| Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study R Aggarwal, J Huang, JJ Alumkal, L Zhang, FY Feng, GV Thomas, ... Journal of Clinical Oncology 36 (24), 2492-2503, 2018 | 654 | 2018 |
| Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance JJ Alumkal, D Sun, E Lu, TM Beer, GV Thomas, E Latour, R Aggarwal, ... Proceedings of the National Academy of Sciences 117 (22), 12315-12323, 2020 | 109 | 2020 |
| TumorMap: exploring the molecular similarities of cancer samples in an interactive portal Y Newton, AM Novak, T Swatloski, DC McColl, S Chopra, K Graim, ... Cancer research 77 (21), e111-e114, 2017 | 80 | 2017 |
| Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity TC Westbrook, X Guan, E Rodansky, D Flores, CJ Liu, AM Udager, ... Nature communications 13 (1), 5345, 2022 | 21 | 2022 |
| Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer R Aggarwal, GR Romero, V Friedl, A Weinstein, A Foye, J Huang, F Feng, ... Prostate cancer and prostatic diseases 24 (1), 81-87, 2021 | 18 | 2021 |
| The genomic and epigenomic landscape of double-negative metastatic prostate cancer A Lundberg, M Zhang, R Aggarwal, H Li, L Zhang, A Foye, M Sjöström, ... Cancer Research 83 (16), 2763-2774, 2023 | 14 | 2023 |
| Copy number loss of 17q22 is associated with enzalutamide resistance and poor prognosis in metastatic castration-resistant prostate cancer X Guan, D Sun, E Lu, JA Urrutia, RE Reiter, M Rettig, CP Evans, P Lara Jr, ... Clinical Cancer Research 26 (17), 4616-4624, 2020 | 10 | 2020 |
| Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer DH Kwon, L Zhang, DA Quigley, A Foye, WS Chen, CK Wong, FY Feng, ... Urologic Oncology: Seminars and Original Investigations 38 (12), 931. e9-931 …, 2020 | 8 | 2020 |
| Using transcriptional signatures to find cancer drivers with LURE D Haan, R Tao, V Friedl, IN Anastopoulos, CK Wong, AS Weinstein, ... Pacific Symposium on Biocomputing 2020, 343-354, 2019 | 7 | 2019 |
| Hydra: A mixture modeling framework for subtyping pediatric cancer cohorts using multimodal gene expression signatures J Pfeil, LM Sanders, I Anastopoulos, AG Lyle, AS Weinstein, Y Xue, ... PLoS computational biology 16 (4), e1007753, 2020 | 4 | 2020 |
| Intermediate atypical carcinoma (IAC): A discrete subtype of metastatic castration-resistant prostate cancer (mCRPC) suggesting that treatment-associated small cell … EJ Small, RR Aggarwal, V Friedl, A Weinstein, GV Thomas, LD True, ... Journal of Clinical Oncology 38 (6_suppl), 158-158, 2020 | 3 | 2020 |
| Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer SG Zhao, M Bootsma, S Zhou, R Shrestha, T Moreno-Rodriguez, ... Nature Genetics, 1-12, 2024 | 1 | 2024 |
| An Atlas of Accessible Chromatin in Advanced Prostate Cancer Reveals the Epigenetic Evolution during Tumor Progression R Shrestha, LN Chesner, M Zhang, S Zhou, A Foye, A Lundberg, ... Cancer Research, 2024 | | 2024 |
| Abstract LB196: An atlas of accessible chromatin in advanced prostate cancer R Shrestha, LN Chesner, M Zhang, S Zhou, A Foye, A Lundberg, ... Cancer Research 84 (7_Supplement), LB196-LB196, 2024 | | 2024 |
| Abstract B012: Genomic and epigenomic drivers of double-negative metastatic prostate cancer A Lundberg, M Zhang, RR Aggarwal, H Li, L Zhang, A Foye, M Sjöström, ... Cancer Research 83 (11_Supplement), B012-B012, 2023 | | 2023 |
| Abstract A029: Whole genome and transcriptome analysis of paired metastatic biopsies identified resistance mechanisms in castration-resistant prostate cancer X Zhu, D Vis, M Sjöström, R Shrestha, J Kneppers, T Severson, Y Zhu, ... Cancer Research 83 (11_Supplement), A029-A029, 2023 | | 2023 |
| Clinical and molecular features of low prostate-specific membrane antigen (PSMA) expression in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). I de Kouchkovsky, L Zhang, J Huang, K Trepka, J Chou, A Foye, D Shui, ... Journal of Clinical Oncology 40 (6_suppl), 167-167, 2022 | | 2022 |
| ADRB2 expression in progressive metastatic castration-resistant prostate cancer. D Kwon, L Zhang, A Foye, WS Chen, FY Feng, A Bailey, J Huang, ... Journal of Clinical Oncology 38 (6_suppl), 145-145, 2020 | | 2020 |
| Clinical and genomic hallmarks of low PSA secretors in metastatic castration-resistant prostate cancer (mCRPC). G Rubio Romero, A Weinstein, V Friedl, A Foye, D Playdle, A Sabol, P Li, ... Journal of Clinical Oncology 37 (15_suppl), 5051-5051, 2019 | | 2019 |
| DNA repair mutations and treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) as hallmarks of distinct subgroups of metastatic castration resistant prostate … RR Aggarwal, P Lloyd, J Huang, TM Beer, L Zhang, GV Thomas, LD True, ... Journal of Clinical Oncology 36 (15_suppl), 5039-5039, 2018 | | 2018 |
Joshua M StuartUC Santa Cruz Genomics Institute在 ucsc.edu 的电子邮件经过验证
